Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for advanced non-small-cell lung cancer (NSCLC) patients. However, most patients will eventually develop resistance. For EGFR-TKI resistance mediated by MET amplification, the combination of EGFR and M...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Boning, Li, Xiaomo, Huang, Xiang, Ma, Tonghui, Qu, Baolin, Yu, Wei, Yang, Wei, Zhang, Pei, Chen, Jing, Liu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674488/
https://www.ncbi.nlm.nih.gov/pubmed/34926253
http://dx.doi.org/10.3389/fonc.2021.738832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674488/
https://www.ncbi.nlm.nih.gov/pubmed/34926253
http://dx.doi.org/10.3389/fonc.2021.738832

Ejemplares similares